Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 92

Sort by

Sort Order Select

Journal Articles

Outcomes in Patients with Cancer-Associated Venous Thromboembolism Receiving Immune Checkpoint Inhibitors: A Matched Cohort Study

Pedro Luiz Lage Bodour Danielian, Heloni M. Dave, Wei Wei, Mehrie H Patel, Dana Elizabeth Angelini, Alok A. Khorana

Blood (2024) 144 (Supplement 1): 5578.

https://doi.org/10.1182/blood-2024-211304

Published: 2024

Journal Articles

Utilization and Clinical Outcomes of an Electronic Best Practice Alert to Prevent Venous Thromboembolism in High-Risk Cancer Patients

Kristi Upadhyaya, Mehrie H Patel, Xiaoying Chen, Alok A. Khorana, Dana Elizabeth Angelini

Blood (2024) 144 (Supplement 1): 2259.

https://doi.org/10.1182/blood-2024-208988

Published: 2024

Journal Articles

Clinical Outcomes of Cancer-Associated Venous Thromboembolism in Patients with Gastrointestinal or Genitourinary Cancers Treated with Direct Oral Anticoagulant Vs. Low Molecular Weight Heparin

Kristi Upadhyaya, Xiaoying Chen, Alok A. Khorana, Dana Elizabeth Angelini

Blood (2024) 144 (Supplement 1): 5086.

https://doi.org/10.1182/blood-2024-211158

Published: 2024

Journal Articles

Immune Checkpoint Blockade Promotes Thrombosis Via T-Cell and Neutrophil Activation, and Tumor-Cell Associated Tissue Factor (TF) in a Murine Model of Colorectal Cancer

Young Jun Shim, Bal Krishan Sharma, Yohei Hisada, Nigel Mackman, Joseph S Palumbo, Claudia Diaz-Montero, Alok A. Khorana, Keith R. McCrae

Blood (2023) 142 (Supplement 1): 1192.

https://doi.org/10.1182/blood-2023-184570

Published: 2023

Journal Articles

Estimating the Burden of Venous and Arterial Thrombotic Events in Hospitalized Adults with COVID-19; A National Multicenter Cohort Study

Rushad Patell, Dana E. Angelini, Stacy R Ellsworth, Paul Lewis, James C Lee, Edith A. Nutescu, Alpesh Amin, Daniel M Witt, Marisol Betensky, Neil Goldenberg, Peter Kouides, Doaa Attia, MD, Lyla Mourany, Leslie Lake, Rachel P. Rosovsky, Alok A. Khorana, Scott Kaatz

Blood (2023) 142 (Supplement 1): 1262.

https://doi.org/10.1182/blood-2023-187029

Published: 2023

Journal Articles

Abnormal metaphase cytogenetics predicts venous thromboembolism in myeloma: derivation and validation of the PRISM score

Rajshekhar Chakraborty, Lisa Rybicki, Wei Wei, Jason Valent, Beth M. Faiman, Christy J. Samaras, Faiz Anwer, Alok A. Khorana

Blood (2022) 140 (23): 2443–2450.

https://doi.org/10.1182/blood.2022015727

Published: 2022

Includes: Supplemental data

Journal Articles

Rivaroxaban Versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism: A Head-to-Head Analysis of the United States Cohort of the Observational Study in Cancer-Associated Thrombosis for Rivaroxaban: (H2H-OSCAR-US)

Kimberly Snow Caroti, Khaled Abdelgawwad, George Psaroudakis, Marcela Rivera, Gunnar Brobert, Alexander T Cohen, Alok A Khorana, Cecilia Becattini, Agnes Y. Lee, Anders Ekbom, Marc Carrier, Craig I. Coleman

Blood (2022) 140 (Supplement 1): 1257–1258.

https://doi.org/10.1182/blood-2022-167801

Published: 2022

Journal Articles

Tissue Factor (TF) Is Upregulated in Tumor-Bearing Mice Treated with Immune Checkpoint Inhibitor (ICI)

Young Jun Shim, Yohei Hisada, Shadi Swaidani, Paul Pavicic, Alok A Khorana, Marcela Diaz-Montero, Nigel Mackman, Keith R. McCrae

Blood (2022) 140 (Supplement 1): 8393–8394.

https://doi.org/10.1182/blood-2022-171043

Published: 2022

Journal Articles

Hemostatic Biomarkers Predict Risk of Thromboembolism (TE), Severe COVID-19 and Mortality: A Report from the National Cancer Institute COVID-19 in Cancer Patients Study (NCCAPS)

Alok A Khorana, Ana Best, Andrea Denicoff, Melissa Bowman, Marwa Shekfeh, Larry V. Rubinstein, Steven A. Pergam, Lisa McShane, Brian Rini, Larissa Korde

Blood (2022) 140 (Supplement 1): 333–335.

https://doi.org/10.1182/blood-2022-158490

Published: 2022

Journal Articles

Comparison of Rivaroxaban and Low Molecular Weight Heparin in the Treatment of Cancer-Associated Venous Thromboembolism

Craig I. Coleman, Kimberly Snow Caroti, Khaled Abdelgawwad, George Psaroudakis, Marcela Rivera, Gunnar Brobert, Alexander T. Cohen, Alok A. Khorana, Cecilia Becattini, Agnes Y. Lee, Anders Ekbom, Marc Carrier

Blood (2022) 140 (Supplement 1): 11368–11369.

https://doi.org/10.1182/blood-2022-166949

Published: 2022

Journal Articles

Immune Checkpoint Inhibitors (ICI) Promote Neutrophil-Platelet Aggregate and NET Formation in Tumor-Bearing Mice

Young Jun Shim, Pat Rayman, Paul Pavicic, Shadi Swaidani, Alok A Khorana, Marcela Diaz-Montero, Keith R. McCrae

Blood (2022) 140 (Supplement 1): 8365–8366.

https://doi.org/10.1182/blood-2022-170687

Published: 2022

Journal Articles

Abundance of B Cell Receptors Harboring Elongated Polytyrosine and Polyserine Rich Motifs within Their Heavy Chain CDR3 Distinguishes Catastrophic and Antiphospholipid Syndrome

Shadi Swaidani, Shruti Chaturvedi, Xiang-Zuo Pan, Robert Brodsky, Renren Wen, Alok A Khorana, Keith R. McCrae

Blood (2021) 138 (Supplement 1): 2117.

https://doi.org/10.1182/blood-2021-148158

Published: 2021

Journal Articles

Risk of Venous Thromboembolism in Patients with Lung Cancer Treated with Immune Checkpoint Inhibitors

Doaa Attia, Wei Wei, Nathan A Pennell, Keith R. McCrae, Alok A Khorana, Pradnya Patil

Blood (2021) 138 (Supplement 1): 3223.

https://doi.org/10.1182/blood-2021-153659

Published: 2021

Journal Articles

Efficacy and Safety of Tinzaparin in CAT Patients with Hematological Malignancy

Agnes Y. Lee, Pieter W. Kamphuisen, Rupert Bauersachs, Nicolas Janus, Randall Leeder, Henrick Thoning, Alok A Khorana

Blood (2021) 138 (Supplement 1): 4273.

https://doi.org/10.1182/blood-2021-145886

Published: 2021

Journal Articles

Risk of Venous Thromboembolism and Survival Outcomes in Patients with Lymphoma

Doaa Attia, Wei Wei, Mailey L. Wilks, Christopher D'Andrea, Alok A Khorana, Dana E. Angelini

Blood (2021) 138 (Supplement 1): 4262.

https://doi.org/10.1182/blood-2021-152321

Published: 2021

Journal Articles

Immune Checkpoint Inhibitors (ICI) Enhance Cancer Associated Thrombosis (CAT) in Murine Model of Colon Carcinoma

Shadi Swaidani, Young Jun Shim, Patricia Rayman, Paul G. Pavicic, C. Marcela Diaz-Montero, Alok A Khorana, Keith R. McCrae

Blood (2021) 138 (Supplement 1): 779.

https://doi.org/10.1182/blood-2021-154228

Published: 2021

Journal Articles

Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors

Blood (2021) 137 (15): 2103–2113.

https://doi.org/10.1182/blood.2020007488

Published: 2021

Includes: Supplemental data

Journal Articles

Abnormal Metaphase Cytogenetics Adds to Currently Known Risk-Factors for Venous Thromboembolism in Multiple Myeloma: Derivation of the PRISM score

Rajshekhar Chakraborty, MD, Lisa Rybicki, MS, Jason Valent, MD, Alex V. Mejia Garcia, MD, Beth M. Faiman, PhDCNP, Jack Khouri, MD, Nathaniel Rosko, PharmD, Christy J. Samaras, DO, Matt Kalaycio, MD, Faiz Anwer, MD, Alok A Khorana, MD

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-137525

Published: 2020

Journal Articles

Frequency of Arterial Thromboemobolic Events in Patients with Cancer Associated Venous Thromboembolism

Doaa Attia, MD, Xuefei Jia, MS, Mailey L Wilks, DNP, MSN, APRN, Barbara Tripp, APRN, CNS, Christopher D'Andrea, PA-C, Keith R McCrae, MD, Alok A Khorana, MD, Dana E Angelini, MD

Blood (2020) 136 (Supplement 1): 37.

https://doi.org/10.1182/blood-2020-136101

Published: 2020

Journal Articles

Thromboembolism in Patients with Advanced Renal Cell Carcinoma Treated with Immunotherapy

Iris Yeong- Fung Sheng, MD, Shilpa Gupta, MD, Chandana A Reddy, MS, Dana E Angelini, MD, Pauline Funchain, MD, Joanna Roopkumar, MBBS, MPH, Tamara A. Sussman, MD, Joseph Sleiman, MD, Timothy D Gilligan, MD, Moshe C Ornstein, MD MA, Alok A Khorana, MD

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-137140

Published: 2020

NARROW

Outcomes in Patients with Cancer-Associated Venous Thromboembolism Receiving Immune Checkpoint Inhibitors: A Matched Cohort Study

Utilization and Clinical Outcomes of an Electronic Best Practice Alert to Prevent Venous Thromboembolism in High-Risk Cancer Patients

Clinical Outcomes of Cancer-Associated Venous Thromboembolism in Patients with Gastrointestinal or Genitourinary Cancers Treated with Direct Oral Anticoagulant Vs. Low Molecular Weight Heparin

Immune Checkpoint Blockade Promotes Thrombosis Via T-Cell and Neutrophil Activation, and Tumor-Cell Associated Tissue Factor (TF) in a Murine Model of Colorectal Cancer

Estimating the Burden of Venous and Arterial Thrombotic Events in Hospitalized Adults with COVID-19; A National Multicenter Cohort Study

Abnormal metaphase cytogenetics predicts venous thromboembolism in myeloma: derivation and validation of the PRISM score

Rivaroxaban Versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism: A Head-to-Head Analysis of the United States Cohort of the Observational Study in Cancer-Associated Thrombosis for Rivaroxaban: (H2H-OSCAR-US)

Tissue Factor (TF) Is Upregulated in Tumor-Bearing Mice Treated with Immune Checkpoint Inhibitor (ICI)

Hemostatic Biomarkers Predict Risk of Thromboembolism (TE), Severe COVID-19 and Mortality: A Report from the National Cancer Institute COVID-19 in Cancer Patients Study (NCCAPS)

Comparison of Rivaroxaban and Low Molecular Weight Heparin in the Treatment of Cancer-Associated Venous Thromboembolism

Immune Checkpoint Inhibitors (ICI) Promote Neutrophil-Platelet Aggregate and NET Formation in Tumor-Bearing Mice

Abundance of B Cell Receptors Harboring Elongated Polytyrosine and Polyserine Rich Motifs within Their Heavy Chain CDR3 Distinguishes Catastrophic and Antiphospholipid Syndrome

Risk of Venous Thromboembolism in Patients with Lung Cancer Treated with Immune Checkpoint Inhibitors

Efficacy and Safety of Tinzaparin in CAT Patients with Hematological Malignancy

Risk of Venous Thromboembolism and Survival Outcomes in Patients with Lymphoma

Immune Checkpoint Inhibitors (ICI) Enhance Cancer Associated Thrombosis (CAT) in Murine Model of Colon Carcinoma

Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors

Abnormal Metaphase Cytogenetics Adds to Currently Known Risk-Factors for Venous Thromboembolism in Multiple Myeloma: Derivation of the PRISM score

Frequency of Arterial Thromboemobolic Events in Patients with Cancer Associated Venous Thromboembolism

Thromboembolism in Patients with Advanced Renal Cell Carcinoma Treated with Immunotherapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only